BOC Sciences bioanalysis service department has a professional scientific research team, the analysis laboratory is equipped with advanced instruments and equipment, and comprehensive information management is implemented. The experimental research meets the requirements of FDA/CFDAGLP standards. The service covers pharmacokinetics, pharmacodynamics, immunogenicity and bioequivalence, and provides customers with screening and development of Antibody-Drug Conjugates (ADCs) drugs, as well as preclinical and clinical research.
ADC has both the specificity of large-molecule drugs and the cytotoxicity of small-molecule drugs, and ADC need to bioquantitate their antibody and small-molecule drug components during the development process. ELISA and LC-MS/MS methods have become common bioanalytical techniques for ADC analysis. Traditionally, the in vivo quantitative analysis of biological macromolecules uses the ELISA method, and small molecule drugs use the LC-MS/MS method. In the process of ADC drug development, structural confirmation, characterization, and quality control are all important links, which must be as accurate, sensitive and selective as possible.
BOC Sciences is equipped with a series of state-of-the-art analytical and preparative UPLC and LC instruments. We can provide our clients with a very comprehensive analysis service.